• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Evogene Ltd

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G 1 evgn-sc13g_123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. __)*

     

    Evogene Ltd.

    (Name of Issuer)

     

    Common Stock 

    (Title of Class of Securities)

     

    M4119S104 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M4119S104 13G Page 2 of 9

     

    1. NAMES OF REPORTING PERSONS

    SilverArc Capital Management, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    3,100,000
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    3,100,000
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,100,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%
    12. TYPE OF REPORTING PERSON (see instructions)

    IA
           

     

     

     

    CUSIP No. M4119S104 13G Page 3 of 9

     

    1. NAMES OF REPORTING PERSONS

    Devesh Gandhi
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    3,100,000
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    3,100,000
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,100,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
           

     

     

     

    CUSIP No. M4119S104 13G Page 4 of 9

     

    Item 1.

     

    (a)Name of Issuer

     

    Evogene Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor 

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    M4119S104

     

     

     

     

    CUSIP No. M4119S104 13G Page 5 of 9

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

    (e)☒ An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

    (g)☒ A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

    (k)☐ Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). 

     

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 3,100,000 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 3,100,000

     

    (b)Percent of Class: 6.1%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 3,100,000

     

    (iii)Sole power to dispose or to direct the disposition of: 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 3,100,000

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 3,100,000

     

    (e)Percent of Class: 6.1%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 3,100,000

     

    (vii)Sole power to dispose or to direct the disposition of: 0.

     

     

     

     

    CUSIP No. M4119S104 13G Page 6 of 9

     

    (viii) Shared power to dispose or to direct the disposition of: 3,100,000.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    ☐As of the date of this Report, the aggregate beneficial ownership of the Reporting Persons had been reduced to below five percent (5%).

     

    Item 6.Ownership of More than Five Percent on Behalf of another Person.

     

    SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 3,100,000 shares, or 6.1% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 3,100,000 shares, or 6.1% of the Common Stock believed to be outstanding.  Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 109,587 of these 3,100,00 shares, which equates to 0.2% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 1,946,922 of these 3,100,000 shares, which equates to 3.8% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 695,935 of these 3,100,000 shares, which equates to 1.4% of the Common Stock believed to be outstanding. Atom Master Fund L.P., a Cayman Islands exempted limited partnership for which SilverArc acts as investment adviser, may be deemed to beneficially own 347,556 of these 3,100,000 shares, which equates to 0.7% of the Common Stock believed to be outstanding.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

    CUSIP No. M4119S104 13G Page 7 of 9

     

    Item 10.Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.

     

    Exhibit A Joint Filing Agreement by and between the Reporting Persons dated February 14, 2024.

     

     

     

     

    CUSIP No. M4119S104 13G Page 8 of 9

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

     

      February 14, 2024
      Date

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi  

     

     

     

     

    CUSIP No. M4119S104 13G Page 9 of 9

     

    EXHIBIT INDEX 

    Ex.  
       
    A Joint Filing Agreement

     

     

    Get the next $EVGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene Reports Second Quarter 2025 Financial Results

    Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

    8/19/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

    A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a range of diseases

    8/12/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Second Quarter 2025 Financial Results Release

    Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

    7/29/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    SEC Filings

    View All

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/19/25 7:00:23 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/18/25 4:01:07 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/11/25 4:01:42 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Reports Second Quarter 2025 Financial Results

    Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

    8/19/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Second Quarter 2025 Financial Results Release

    Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

    7/29/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports First Quarter 2025 Financial Results

    Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe

    5/21/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

    A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a range of diseases

    8/12/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

    Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

    3/6/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

    Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

    12/19/23 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials